{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:45:45Z","timestamp":1786135545518,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nrleng.2026.502139","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:20:20Z","timestamp":1785424820000},"page":"502139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-life effectiveness, tolerability, and safety of atogepant: a prospective, observational, multicentre study by the Headache Study Group in Castile-La Mancha"],"prefix":"10.1016","author":[{"given":"Marcos","family":"Calvo Alzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Garrido Robres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Francisco","family":"Cano Vargas-Machuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"\u00c1vila Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Andr\u00e9s L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Pay\u00e1 Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n Ernesto","family":"Ib\u00e1\u00f1ez Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Flores Barrag\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"S\u00e1nchez Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Jos\u00e9","family":"Castellano Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Navarro Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10283","key":"10.1016\/j.nrleng.2026.502139_bib0005","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","article-title":"Migraine: epidemiology and systems of care","volume":"397","author":"Ashina","year":"2021","journal-title":"The Lancet [Internet]"},{"key":"10.1016\/j.nrleng.2026.502139_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J Headache Pain"},{"key":"10.1016\/j.nrleng.2026.502139_bib0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40120-020-00196-2","article-title":"The humanistic and economic burden of migraine in Europe: a cross-sectional survey in five countries","volume":"9","author":"Doane","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1016\/j.nrleng.2026.502139_bib0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-024-01740-3","article-title":"Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey","volume":"25","author":"Garc\u00eda-Azor\u00edn","year":"2024","journal-title":"J Headache Pain"},{"key":"10.1016\/j.nrleng.2026.502139_bib0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s10194-025-02069-1","article-title":"Prevalence, disability, and economic impact of migraine in Spain: a nationwide population-based study","volume":"26","author":"Sanchez-del-Rio","year":"2025","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.nrleng.2026.502139_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.nrleng.2026.502139_bib0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2026.502139_bib0040","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2026.502139_bib0045","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2026.502139_bib0050","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nrleng.2026.502139_bib0055","doi-asserted-by":"crossref","DOI":"10.1152\/physrev.00059.2021","article-title":"CGRP physiology, pharmacology, and therapeutic targets: Migraine and beyond","volume":"103","author":"Russo","year":"2022","journal-title":"Physiol Rev"},{"key":"10.1016\/j.nrleng.2026.502139_bib0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/B978-0-12-823357-3.00024-0","article-title":"CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention","volume":"199","author":"Caronna","year":"2024","journal-title":"Handb Clin Neurol"},{"issue":"10419","key":"10.1016\/j.nrleng.2026.502139_bib0065","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0140-6736(23)01683-5","article-title":"Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA","volume":"402","author":"Dodick","year":"2023","journal-title":"The Lancet [Internet]"},{"issue":"3","key":"10.1016\/j.nrleng.2026.502139_bib0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","article-title":"Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial","volume":"22","author":"Lipton","year":"2023","journal-title":"Lancet Neurol [Internet]"},{"issue":"10200","key":"10.1016\/j.nrleng.2026.502139_bib0075","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet"},{"issue":"10268","key":"10.1016\/j.nrleng.2026.502139_bib0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet [Internet]"},{"issue":"8","key":"10.1016\/j.nrleng.2026.502139_bib0085","first-page":"e764","article-title":"Effect of atogepant for preventive migraine treatment on patient-reported outcomes in the randomized, double-blind, phase 3 ADVANCE trial","volume":"100","author":"Lipton","year":"2023","journal-title":"Neurology [Internet]"},{"issue":"10404","key":"10.1016\/j.nrleng.2026.502139_bib0090","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","article-title":"Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Pozo-Rosich","year":"2023","journal-title":"Lancet [Internet]"},{"key":"10.1016\/j.nrleng.2026.502139_bib0095","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(24)00025-5","article-title":"Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial","volume":"23","author":"Tassorelli","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2026.502139_bib0100","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.nrleng.2026.502139_bib0105","doi-asserted-by":"crossref","DOI":"10.1177\/03331024251318016","article-title":"Guidelines of the International Headache Society for real-world evidence studies in migraine and cluster headache","volume":"45","author":"Pozo-Rosich","year":"2025","journal-title":"Cephalalgia"},{"key":"10.1016\/j.nrleng.2026.502139_bib0110","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMp2200089","article-title":"Real-world evidence \u2014 where are we now?","volume":"386","author":"Concato","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.nrleng.2026.502139_bib0115","doi-asserted-by":"crossref","DOI":"10.1177\/03331024251335927","article-title":"Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study)","volume":"45","author":"Vernieri","year":"2025","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.nrleng.2026.502139_bib0120","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-025-02068-2","article-title":"GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures","volume":"26","author":"Barbanti","year":"2025","journal-title":"J Headache Pain"},{"issue":"6","key":"10.1016\/j.nrleng.2026.502139_bib0125","doi-asserted-by":"crossref","DOI":"10.1177\/03331024251346925","article-title":"Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study","volume":"45","author":"Jaimes","year":"2025","journal-title":"Cephalalgia"},{"issue":"8","key":"10.1016\/j.nrleng.2026.502139_bib0130","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1093\/brain\/awae062","article-title":"Novel insight into atogepant mechanisms of action in migraine prevention","volume":"147","author":"Melo-Carrillo","year":"2024","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.nrleng.2026.502139_bib0135","article-title":"Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: updated analysis in VigiBase\u00ae","volume":"43","author":"Noseda","year":"2023","journal-title":"Cephalalgia [Internet]"},{"issue":"8","key":"10.1016\/j.nrleng.2026.502139_bib0140","first-page":"1","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat Rev Neurol [Internet]"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826001276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580826001276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:45:29Z","timestamp":1786131929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580826001276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"alternative-id":["S2173580826001276"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502139","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life effectiveness, tolerability, and safety of atogepant: a prospective, observational, multicentre study by the Headache Study Group in Castile-La Mancha","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2026.502139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2026.502139","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502139"}}